Synthetic cannabinoids: the hidden side of Spice drugs

被引:24
作者
Pintori, Nicholas [1 ]
Loi, Barbara [3 ]
Mereu, Maddalena [2 ]
机构
[1] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy
[2] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Largo Meneghetti 2, I-35131 Padua, Italy
[3] Univ Hertfordshire, Dept Pharm Postgrad Med & Pharmacol, Psychopharmacol Drug Misuse & Novel Psychoact Sub, Hatfield, Herts, England
来源
BEHAVIOURAL PHARMACOLOGY | 2017年 / 28卷 / 06期
关键词
addiction; novel psychoactive substances; spice drugs; synthetic cannabinoids; INTRACRANIAL SELF-STIMULATION; NUCLEUS-ACCUMBENS SHELL; DOPAMINE TRANSMISSION; IN-VIVO; DESIGNER DRUGS; JWH-073; ABUSE; RESPONSIVENESS; INTOXICATION; WIN-55,212-2;
D O I
10.1097/FBP.0000000000000323
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Spice drugs are herbal mixtures sprayed with synthetic cannabinoids designed to mimic the psychoactive ingredient in marijuana [(9)-tetrahydrocannabinol ((9)-THC)] and synthesized by introducing modifications to the chemical structure of parental compounds aiming to circumvent legal regulations. Synthetic cannabinoid use/abuse can be devastating as toxicological effects and adverse reactions cannot be entirely predicted and may vary with the dose, route of administration, individual vulnerability and concomitant intake with other drugs. The absence of validated testing procedures in the clinical field makes difficult the adoption of a therapeutic approach effective in coping with the synthetic cannabinoid phenomenon, posing a significant challenge for prevention, treatment and public health in general. The aim of this review is to gain insights into the epidemiological, pharmacological and toxicological properties of synthetic cannabinoids, aiming to provide a reliable background needed for the management of synthetic cannabinoid-related adverse effects. Consumers, competent authorities and medical care professionals should be aware of the risks associated with synthetic cannabinoid use. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:409 / 419
页数:11
相关论文
共 69 条
[1]  
[Anonymous], 2014, FORENSIC SCI REV
[2]  
[Anonymous], 2009, Understanding the Spice' phenomenon, P1
[3]  
Antoniou T, 2014, CAN MED ASSOC J, V186, P210, DOI [10.1097/MAJ.0000000000000466, 10.1503/cmaj.130510]
[4]   CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB1 cannabinoid receptor agonists [J].
Atwood, Brady K. ;
Lee, Donghoon ;
Straiker, Alex ;
Widlanski, Theodore S. ;
Mackie, Ken .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 659 (2-3) :139-145
[5]   Patterns of synthetic cannabinoid use in Australia [J].
Barratt, Monica J. ;
Cakic, Vince ;
Lenton, Simon .
DRUG AND ALCOHOL REVIEW, 2013, 32 (02) :141-146
[6]   Spice: A New "Legal" Herbal Mixture Abused by Young Active Duty Military Personnel [J].
Bebarta, Vikhyat S. ;
Ramirez, Sasha ;
Varney, Shawn M. .
SUBSTANCE ABUSE, 2012, 33 (02) :191-194
[7]   Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22 [J].
Behonick, George ;
Shanks, Kevin G. ;
Firchau, Dennis J. ;
Mathur, Gagan ;
Lynch, Charles F. ;
Nashelsky, Marcus ;
Jaskierny, David J. ;
Meroueh, Chady .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2014, 38 (08) :559-562
[8]   Lesion of medial prefrontal dopamine terminals abolishes habituation of accumbens shell dopamine responsiveness to taste stimuli [J].
Bimpisidis, Zisis ;
De Luca, Maria Antonietta ;
Pisanu, Augusta ;
Di Chiara, Gaetano .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2013, 37 (04) :613-622
[9]   The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products [J].
Brents, Lisa K. ;
Prather, Paul L. .
DRUG METABOLISM REVIEWS, 2014, 46 (01) :72-85
[10]   Differential Drug-Drug Interactions of the Synthetic Cannabinoids JWH-018 and JWH-073: Implications for Drug Abuse Liability and Pain Therapy [J].
Brents, Lisa K. ;
Zimmerman, Sarah M. ;
Saffell, Amanda R. ;
Prather, Paul L. ;
Fantegrossi, William E. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 346 (03) :350-361